Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2021 07:30 ET | Source: MacroGenics, Inc.

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...
May 19, 2021 17:05 ET | Source: MacroGenics, Inc.

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction;...
May 19, 2021 07:00 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, May 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
April 29, 2021 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCOConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md., April 29, 2021 ...
April 19, 2021 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
April 10, 2021 08:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Presentations at the 2021 AACR Annual Meeting

ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
February 26, 2021 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
February 25, 2021 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results

MARGENZA™ approved in December 2020; commercial launch expected March 2021July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumabMultiple clinical updates across...
February 18, 2021 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
February 11, 2021 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Names Federica O’Brien to its Board of Directors

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...